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Background: Achieving lifelong tobacco abstinence is an important public health goal. Most studies use 1-year
follow-ups, but little is known about how good these are as proxies for long-term and life-long abstinence. Also,
intervention intensity is an important issue for development of efficient and cost-effective cessation treatment
protocols.
The study aims were to assess the long-term effectiveness of a high- and a low-intensity treatment (HIT and LIT) for
smoking cessation and to analyze to what extent 12-month abstinence predicted long-term abstinence.
Methods: 300 smokers attending dental or general health care were randomly assigned to HIT or LIT at the public
dental clinic. Main outcome measures were self-reported point prevalence, continuous abstinence (≥6 months),
and sustained abstinence. The study was a follow-up after 5–8 years of a previously performed 12-month follow-up,
both by postal questionnaires.
Results: Response rate was 85% (n=241) of those still alive and living in Sweden. Abstinence rates were 8% higher
in both programs at the long-term than at the 12-month follow-up. The difference of 7% between HIT and LIT had
not change, being 31% vs. 24% for point prevalence and 26% vs. 19% for 6-month continuous abstinence,
respectively. Significantly more participants in HIT (12%) than in LIT (5%) had been sustained abstinent (p=0.03).
Logistic regression analyses showed that abstinence at 12-month follow-up was a strong predictor for abstinence at
long-term follow-up.
Conclusions: Abstinence at 12-month follow-up is a good predictor for long-term abstinence. The difference in
outcome between HIT and LIT for smoking cessation remains at least 5–8 years after the intervention.
Trial registration number: NCT00670514
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Tobacco use causes nearly six million deaths globally every
year [1]. There is strong evidence that quitting smoking
improves health and reduces the risk of premature death
[2-4]. Achieving lifelong abstinence is therefore an impor-
tant public health goal and thus a goal for tobacco control
policies and smoking cessation treatment [5].
There is a vast literature on and strong evidence for
the effectiveness of tobacco control programs [6], and a
recent review concludes that interventions for tobacco* Correspondence: eva.nohlert@ltv.se
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reproduction in any medium, provided the orcessation in the dental setting significantly can increase
tobacco cessation rates [7]. It is also widely acknowl-
edged that tobacco cessation programs are cost-effective,
ranging from a few hundred to a few thousand dollars
per Quality Adjusted Life Year (QALY) [6,8,9]. Behav-
ioral support and medication, especially in combination,
are effective and highly cost-effective as life-saving inter-
ventions [10]. The evidence for the efficacy of Nicotine
Replacement Therapy (NRT) from clinical trials [6,11]
has, however, in real-life situations, been somewhat
conflicting [12-15]. There are a number of reported pre-
dictors for successful quitting, e.g. high motivation, low
number of smoked cigarettes per day, high socioeconomicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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port, gender (mostly being a man), and higher age [6,16,17].
The international literature indicates that 6-12% of
smokers trying to quit are abstinent 12 months later if no
support is available [6]. The majority of smokers make a
number of quit attempts before they eventually achieve
sustained abstinence [5,6]. Relapse to smoking after a quit-
ting attempt is greatest in the first few weeks, then dec-
reases rapidly over time and the longer the period of
abstinence, the lower the rate of relapse [18-20]. Most
studies report follow-up results up to 1 year [21], but less
is known about to what extent being smoke-free at
12 months predicts more long-term abstinence. There is a
general lack of clinical studies with long-term follow-up
and, especially, studies that compare interventions with
different intensity in a real-world clinical context not fo-
cusing on specific pharmaceuticals. Uncertainty remains
regarding the optimal intensity of interventions, overall,
and for different groups of smokers, but most studies indi-
cate that high-intensity programs lead to higher rates of
cessation [6,8,22-24]. The question of intensity of a smo-
king cessation program is important, because if a minimal
intervention can result in even a small increase in cessa-
tion rates, this would have a large public health impact.
Even though Sweden has succeeded in reducing the
prevalence of tobacco smoking, smokeless tobacco (snus)
use is relatively common. Currently, 1.6 million Swedes
(21% 2011) use tobacco every day, with great differences
existing between different socioeconomic groups [25]. Al-
though over 70% of daily smokers state that they want to
quit (at least some time), the overall spontaneous smoking
quit rate in the population has been only 1-2% per year
[25]. Smoking is still the single most important risk factor
for disease and premature death and, in coming decades,
the supply of smoking cessation aids and support will be
the most important elements of tobacco control [25,26].
However, the societal and, in particular, the healthcare sys-
tem resources are strained to meet the need for cessation
support, which emphasizes the need for further develop-
ment of effective and cost-effective tobacco cessation
methods [26,27].
The primary aim of the present study was to assess the
long-term effectiveness of a high- and a low-intensity
treatment for smoking cessation and the secondary aim
was to analyze predictors for long-term abstinence. The
basis for the present study is a randomized controlled trial
(RCT) consisting of two programs of different intensity
with a previous follow-up after 12 months [28].
Methods
This study was a long-term follow-up of a previously
reported study [28]. In the original intervention study,
between August 2003 and February 2005, 300 smokers
recruited via direct inquiry or advertising in dental orgeneral health care were offered smoking cessation sup-
port performed in a dental setting. Inclusion criteria
were daily smokers over 20 years of age. Excluded were
individuals with reading difficulties and those not fluent
in the Swedish language. The participants were randomly
assigned to two study arms; one received high-intensity and
the other low-intensity treatment support. The participants
answered a baseline questionnaire and a follow-up ques-
tionnaire that was sent by mail 12 months after the planned
smoking cessation date.
The long-term follow-up was performed 5–8 years after
the planned smoking cessation dates. We developed a
questionnaire with 13 questions, of which all were vali-
dated questions and eleven were previously used in the
baseline and the 12-month questionnaires [28]. The ques-
tionnaire was pre-tested in 10 ex-smokers. The questions
included smoking habits, amount, intention to quit (if still
smoking), and use of snus, NRT, Champix®, Zyban®, and
other support (social and/or other professional).
Before sending the questionnaires, the national popu-
lation register was checked for deaths and emigration.
The questionnaire was posted to the participants to-
gether with a cover letter and an informed consent form.
Participants were asked to return the answered ques-
tionnaire and signed consent form in the enclosed pre-
paid envelope. Those still not answering after two
written reminders were contacted and interviewed by
telephone by a dental hygienist.
The original study, as well as the long-term follow-
up, was approved by the ethical committee at Uppsala
University (Dnr:Ups 02–457, Dnr: 2010/172).
Treatment protocols
In the original study [28], all counselling was carried out
by three dental hygienists educated and trained in ge-
neral smoking cessation support methods who had re-
ceived additional training in the specific programs used
in the study.
The High-Intensity Treatment program (HIT) com-
prised eight 40-minute individual sessions over a period of
four months. The program was a traditional state of the
art smoking cessation program based on a mixture of be-
haviour therapy, coaching, and pharmacological advice.
The Low-Intensity Treatment program (LIT) consisted
of one 30-minute counselling session focused on ex-
plaining the content of a traditional self-help program (in
Swedish “Fimpa dig fri”). The leaflet contained an 8-week
program with instructions and tasks to perform each week
including several tests and behaviour registration exercises
suggesting different action plans for different outcomes. In
general, both the self-help and the clinic-based program
were based on similar treatment protocols.
Information on possible benefits of NRT was included
with both programs, but the participants received no
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meeting, a smoking cessation date was fixed for all par-
ticipants in both groups. The participants were informed
that they would be followed-up. Both programs were
free of charge.
Questionnaire and outcome measures
Abstinence was assessed with the question: Have you
smoked during the past seven days? The answer alterna-
tives were: Yes, daily; Yes, but not daily; No, I have not
smoked at all. Those who answered that they had not
smoked during the past seven days answered an ad-
ditional question about their last smoking date.
Point prevalence abstinence was defined as self-
reported: “not one puff of smoke during the past seven
days”, and 6-month continuous abstinence as: “not one
puff of smoke during the past six months (183 days)”
[29]. Those reporting to be occasional smokers were
classified as point prevalence abstinent, but as smokers
according to 6-month continuous abstinence if they
had not smoked during the past seven days. Those
classified as sustained abstinent quit at the fixed smok-
ing cessation date and had not smoked at all since then.
(Additional file 1: Figure S1).
Statistics
We used the “intention-to-treat” approach where all par-
ticipants were included in the analyses according to the
program they were randomized to. When measuring ab-
stinence at follow-up, non-responders to the follow-up
questionnaire were treated as smokers. However, we also
analysed responder-only abstinence. For six individuals
who did not reply to the baseline questionnaire, we only
had information about their gender and which program
they were randomized to, thus they could not be used in
the analyses of background variables.
Chi-square test and Fisher´s exact test were used for
comparisons between HIT and LIT for categorical varia-
bles and Mann–Whitney U-test for continuous variables.
Wilcoxon Signed Rank Test was used to test change in
number of smoked cigarettes at baseline and at long-
term follow-up in still smokers. Logistic regression ana-
lysis was performed to calculate odds ratios (ORs) with a
95% confidence interval for the three different outcome
measures. We first made univariable analyses of all rele-
vant independent variables. As the purpose was to ob-
tain a predictive model, statistical significant variables at
p<0.2 in the univariable analyses at baseline and at 12-
month follow-up, plus program and gender, were in-
cluded in the multivariable analyses. The multivariable
analyses were performed with forward and backward
stepwise likelihood ratio test (LR), to detect potential
collinearity that could disturb the analyses, with 5% for
inclusion and 5% for exclusion. Hosmer and Lemeshowgoodness of fit test was used for testing the overall fit of
the logistic regression model [30]. The statistical ana-
lyses were performed using the Statistical Package for
Social Sciences (SPSS, version 20.0). Statistical signifi-
cance was set to p<0.05.Results
Of the original 300 smokers, twelve had died and four had
emigrated, leaving 284 possible individuals to contact for
the long-term follow-up. Of these, 178 (63%) returned an
answered questionnaire and thirteen returned an un-
answered questionnaire but often with a comment which,
in five cases, included information of their actual smoking
status. By means of telephone calls to those 93 participants
who had not returned the questionnaire, an additional 63
answers were retrieved, giving a total percentage of an-
swers of 85% (241/284), 86% in HIT and 84% in LIT.
Women constituted 81% of the respondents. The study´s
flowchart is presented in Figure 1 and some baseline cha-
racteristics of the participants in Table 1.
The median follow-up time was 6.2 (q1 5.9; q3 6.7)
years (HIT median 6.1, q1 5.8; q3 6.7, LIT median 6.3, q1
6.0; q3 6.8, p=0.135). It was measured from the planned
cessation date until the date when the questionnaire was
completed or the telephone interview was performed.Abstinence/outcome, length of abstinence/time to
first stop
Point prevalence was 31% in HIT and 24% in LIT, and
6-month continuous abstinence 26% in HIT and 19% in
LIT. These differences in abstinence rates between the
programs were not statistically significant. However,
when analyzing the proportion of participants who had
maintained sustained abstinence, there was a significant
difference in favor of HIT: 12% vs. 5% (p=0.030). The
differences in quit rates between HIT and LIT and the
p-values were almost the same in ITT- and in
responder-only analyses (Table 1, Figure 2).
The mean number of smoke-free days immediately be-
fore the long-term follow up was 1317 (SD 942) in HIT
and 1194 (SD 894) in LIT (not significant). However, the
number of days from baseline assessment to first quit
was significantly shorter in HIT (median 185) than in
LIT (median 502) (p=0.025).Amount of cigarettes
The number of smoked cigarettes per week decreased
from baseline (median=105, interquartile range=70) to
long-term follow-up (median=84, interquartile range=49)
in still smokers with median=14, interquartile range=40;
p<0.001. This reduction was significantly higher in HIT
than in LIT (p=0.042).
Figure 1 Flowchart of the study. (Through returned unanswered questionnaires with comments, information about smoking status at long-term
follow-up was given for one in HIT (who was smokefree) and four in LIT (one was smoke-free). That is the reason for N3=284 while the sum of the
lower boxes is 282).
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About two-thirds of the participants stated that they had
had access to other support, mainly social (from family,
friends, and workmates). Abstinence rates were signifi-
cantly higher among those with other support than
among those without, regarding point prevalence 36%
vs. 21% (p=0.017) and 6-month continuous abstinence
29% vs. 16% (p=0.034). However, 10% had maintained
sustained abstinence, both among those with and with-
out other support.
Access to other support was equal in both programs,
but in LIT there were significantly higher abstinence rates
among those with other support than among those with-
out. Point prevalence was 33% vs. 12% (p=0.025) and
6-month continuous abstinence 27% vs. 9% (p=0.040).
Gender differences
Women had higher, although non-significant, abstinence
rates than men at the long-term follow-up. Point
prevalence was 30% among women and 17% among
men (p=0.051), and 6-month continuous abstinence
24% among women and 15% among men (p=0.171).
The difference between women and men was larger at
the long-term than at the 12-month follow-up. Access to
other support was significantly higher among women (73%)
than among men (53%) (p=0.015).When analyzing gender differences in HIT and LIT
separately, the only significant difference was that, in
HIT, more women than men had access to other support
(p=0.003).
Pharmaceuticals
Twenty-two percent of all participants had used pharma-
ceuticals for smoking cessation (NRT, Zyban®, Champix®)
during the week before the long-term follow-up, com-
pared with 16% at the 12-month assessment (NRT)
and 8% at baseline (NRT), with similar proportions in
both programs.
Since the program-start, 24% had used NRT ≥5 weeks,
30% <5 weeks, and 47% had not used it at all, with similar
proportions in HIT and LIT. The effect of NRT-use on
abstinence did not differ significantly between HIT and
LIT (Additional file 2: Table S1). No difference in ab-
stinence rates was detected between those who had used
NRT ≥5 weeks and those who had not used NRT at all
since the program start. However, those who had used
NRT <5 weeks were significantly less likely to be abstin-
ent compared with those who had used it ≥5 weeks or
not at all. We found a significant association between
NRT-use (none or ≥5 weeks compared to <5 weeks) and
abstinence, controlling for program (for point preva-
lence OR=0.31, p=0.001 and for 6-month continuous








(nHIT = 141) (nLIT = 143)
Gender:
Men 20 (58/284) 18 (26/141) 22 (32/143) .410
Women 80 (226/284) 82 (115/141) 78 (111/143)
Age at baseline†:
mean (SD) 48.6 (10.3) 48.7 (9.6) 48.5 (11.0)
median 49.0 48.0 49.0 .825
quartiles 42.0; 56.0 42.0; 56.0 41.0; 56.0
Education in years†:
0 - 9 22 (61/278) 18 (25/137) 26 (36/141) .336
10 - 12 41 (115/278) 44 (60/137) 39 (55/141)
≥ 13 37 (102/278) 38 (52/137) 35 (50/141)
Number of smoked cigarettes/week at baseline†:
mean (SD) 106 (45) 106 (50) 105 (40)
median 105 105 105 .794
quartiles 70; 140 70; 140 70; 140
Intention to quit at baseline†:
not within 6 months 1 (4/278) 1 (1/137) 2 (3/141) .120¶
within 6 months 50 (139/278) 46 (63/137) 54 (76/141)
within 1 month 48 (133/278) 52 (71/137) 44 (62/141)
trying just now 1 (2/278) 1 (2/137) 0 (0/141)
12-month follow-up:
Point prevalence abstinence‡ 19 (55/284) 23 (32/141) 16 (23/143) .159
of which:
< 6 months 5 (15/284) 4 (6/141) 6 (9/143) .443
≥ 6 months§ 14 (40/284) 18 (26/141) 10 (14/143) .036
Long-term follow-up:
Point prevalence abstinence 27 (78/284)‡ 31 (44/141)‡ 24 (34/143)‡ .161
31 (76/241)║ 35 (43/121)║ 27 (33/120)║ .179
6-month continuous abstinence 22 (63/284)‡ 26 (36/141)‡ 19 (27/143)‡ .177
25 (61/241)║ 29 (35/121)║ 22 (26/120)║ .195
Sustained abstinence 9 (24/284)‡ 12 (17/141)‡ 5 (7/143)‡ .030
10 (24/241)║ 14 (17/121)║ 6 (7/120)║ .033
* Statistical significant difference between HIT and LIT tested with chi-square test, except for age and number of cigarettes at baseline which were tested
with Mann–Whitney U-test.
† Information from 278 participants (137 HIT, 141 LIT) because six did not reply to the baseline questionnaire.
‡ According to intention-to-treat, non-responders treated as smokers.
§ Equal to 6-month continuous abstinence.
║ Responder-only abstinence.
¶ p-value for grouping into “not within 6 months/within 6 months” vs. “within 1 month/trying just now” because 4 cells (50.0%) had expected count less than 5 in
the original grouping.
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S2). Zyban® was used by 14% (31/224) and Champix® by
14% (31/224) since the program-start, with similar pro-
portions in both programs.Snus
Eight percent used snus during the week before the long-
term follow-up, compared with 6% at the 12-month
assessment and 7% at baseline. There were slightly higher
Figure 2 Outcomes for HIT and LIT at 12-month and at long-term (5–8 ys) follow-up. (PP=point prevalence abstinence, CA=6-month
continuous abstinence, SA = sustained abstinence).
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statistically significant.
Still trying
Of the participants responding to the follow-up and who
were still smoking, 63% (105/166) were actually trying to
quit at that time or intended to make a new attempt
within the following six months, with no significant dif-
ferences between the programs.
Logistic regression analyses
In the multivariable analyses, we adjusted for significant
confounders up to the 12-month follow-up, plus program
and gender and the results are presented in Table 2.
Point prevalence and 6-month continuous abstinence at
the 12-month follow-up were strong predictors for
point prevalence as well as for 6-month continuous ab-
stinence at the long-term follow-up, when controlled
for program and gender. Program (HIT) was the only
significant predictor of sustained abstinence, controlled
for gender and NRT use between baseline and 12-month
follow-up. The results of the univariable analyses for the
three outcomes, respectively, are presented in Additional
file 4: Table S3, Additional file 5: Table S4 and Additional
file 6: Table S5.
Transitions between smoking statuses from 12-month to
long-term follow-up
At 12-month follow-up the participants were in one
of three smoking statuses: smokers, point prevalent
but <6 months abstinent or 6-month continuous abstinent.
Here we describe the transition between smoking statuses
from 12-month to long-term follow-up for these three
statuses. Among those who were smokers at the 12-monthfollow-up, 83% were still smokers at the long-term follow-
up and 17% were smokefree (12% had been abstinent for at
least 6 months), with equal proportions in HIT and LIT.
Among those who were point prevalent but <6 months at
the 12-month follow-up, 40% were smokers at the long-
term follow-up and 60% were smokefree (40% had been
abstinent for at least 6 months). In this group the program
effects differed: in HIT 17% were smokers and 83% were
smoke-free (50% had been abstinent for at least 6 months),
and in LIT 56% were smokers and 44% were smoke-free
(33% had been abstinent for at least 6 months). However,
since there were only 15 participants in this group, it
was not possible to test statistical significance between
the programs. Among those who were 6-month continuous
abstinent at the 12-month follow-up, 23% were smokers
at the long-term follow-up and 77% were smokefree
(75% had been abstinent for at least 6 months). In this group
the difference between HIT and LIT was smaller; however, a
larger proportion smoked at the long-term follow-up in LIT
than in HIT, and a larger proportion was smokefree in HIT
than in LIT. (Additional file 7: Figure S2).
In drop-out analyses we compared the baseline charac-
teristics and 12-month variables of responders (n=241)
with non-responders (n=43) at the long-term follow-up.
The non-responders had higher cigarette consumption
at baseline and at 12-month follow-up (p=0.010 and
p=0.025). No other differences were seen between the res-
ponders and non-responders. We also compared those an-
swering via questionnaire with those answering via
telephone, and found more non-smokers among the
questionnaire-responders and more smokers among the
telephone-responders (p=0.001). Five participants who did
not reply to the 12-month follow-up were smoke-free at
the long-term follow-up.
Table 2 Multivariable logistic regression analyses* for point prevalence abstinence†, 6-month continuous abstinence†,
and sustained abstinence
Point prevalence abstinence †
Variable OR 95% CI for OR p-value
‡ Program; HIT vs. LIT (ref) 1.21 0.59-2.49 .599
‡ Gender; men vs. women (ref) 0.54 0.20-1.46 .226
‡ Point prevalence at 12-month follow-up; yes vs. no (ref) 13.82 6.44–29.65 <.001
‡ Other support at 12-month follow-up; yes vs. no (ref) 4.37 1.13–16.95 .033
§ Program; HIT vs. LIT (ref) 1.12 0.56-2.26 .751
§ Gender; men vs. women (ref) 0.67 0.26-1.71 .405
§ 6-month continuous abstinence at 12-month follow-up; yes vs. no (ref) 13.53 5.66–32.32 <.001
§ Other support at 12-month follow-up; yes vs. no (ref) 4.95 1.30–18.85 .019
6-month continuous abstinence †
Variable OR 95% CI for OR p-value
║ Program; HIT vs. LIT (ref) 1.26 0.65-2.43 .487
║ Gender; men vs. women (ref) 0.55 0.23-1.35 .193
║ Point prevalence at 12-month follow-up; yes vs. no (ref) 14.10 7.05–28.19 <.001
¶ Program; HIT vs. LIT (ref) 1.10 0.57-2.13 .779
¶ Gender; men vs. women (ref) 0.62 0.26-1.51 .297
¶ 6-month continuous abstinence at 12-month follow-up; yes vs. no (ref) 18.70 8.30–42.16 <.001
Sustained abstinence **
Variable OR 95% CI for OR p-value
Program; HIT vs. LIT (ref) 3.44 1.34–8.83 .010
Gender; men vs. women (ref) 1.21 0.41-3.60 .733
* Performed with variables significant at p<0.02 in the univariable analyses, only including variables up to 12-month follow-up.
† Separate models for point prevalence at 12-month follow-up and for 6-month continuous abstinence at 12-month follow-up.
‡ N=210, Nagelkerke R-Square 39.2%, Hosmer and Lemeshow test of goodness of fit p=0.884.
§ N=210, Nagelkerke R-Square 33.5%, Hosmer and Lemeshow test of goodness of fit p=0.920.
║N=284, Nagelkerke R-Square 31.7%, Hosmer and Lemeshow test of goodness of fit p=0.969.
¶ N=284, Nagelkerke R-Square 30.7%, Hosmer and Lemeshow test of goodness of fit p=0.932.
** N=210, Nagelkerke R-Square 11.7%, Hosmer and Lemeshow test of goodness of fit p=0.970.
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At the long-term follow-up 5–8 years after the planned
smoking cessation date, 27% of the participants were abs-
tinent. Point prevalence was 31% in HIT and 24% in LIT,
of which 26% and 19%, respectively, was 6-month con-
tinuous abstinence. Sustained abstinence was maintained
by 12% in HIT and 7% in LIT (p=0.03). The 7% difference
in abstinence rates between HIT and LIT remained
unchanged over time and may be considered clinically
significant because of the very large health gains that ac-
crue from stopping smoking and which are attached to
cost-savings [31]. The proportion of smoke-free partici-
pants had increased by 8% from the 12-month to the
long-term follow-up in both treatment arms. Abstin-
ence at the 12-month follow-up was a strong predictor
for abstinence at the long-term follow-up. A probable
theoretical explanation of the observed difference be-
tween the treatment arms is that structured long-term
contact may increase the possibilities for being exposedto positive reinforcement and skills training delivered by
the counsellor.
Returning to our question in the introduction: how good
are 1-year follow-ups as proxies for long-term and life-long
abstinence? Other studies report that, among 12-month
abstainers, 60-70% remains abstinent for at least eight years
[21,32]. We found that abstinence rates increased by 8%
from 12-month to long-term (5-8 yrs) follow-up in both
programs, and that abstinence at 12-month follow-up was
the strongest predictor of long-term abstinence. However,
regarding differences between the programs, we found that
the group with point prevalence but <6 months at the
12-month follow-up was crucial; HIT had more abstinent
participants and fewer smokers at long-term follow-up
compared with LIT. Thus, a possibility could be to offer
some kind of renewed support after one year to participants
in this group, which needs to be studied further.
As far as we know, there is a lack of non-pharmacological
clinical studies with long-term follow-up and, consequently,
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gram in a specialist clinic in Sweden, with an average of 10
treatment sessions and NRT as a recommended part of the
program, shows 40% abstinence after 5–7 years, of which
18% is continuous abstinence [33]. In the comprehensive
American Lung Health Study (LHS) with long-term follow-
up, smokers with mild airway obstruction are randomized
to either an intensive 12-week smoking cessation interven-
tion (SI) including nicotine gum and repeated follow-up
visits/contacts or to usual care (UC). Point prevalence
abstinence is high and increases in both programs over
time, in SI 39% after 5 years and 52% after 11 years, in UC
22% and 43%, respectively. Participants with sustained
abstinence for the first 5-year period are very likely to still
be abstinent after 11 years, when validated sustained abstin-
ence is 22% for SI and 6% for UC [34,35]. Blondal et al. re-
port 9% sustained abstinence after six years among smokers
in Iceland receiving nicotine patches for five months and 10
individual and group meetings [36].
In Sweden, 85-90% of the adult inhabitants regularly
visit the dental care [25,37]. The present study, performed
in a public dental setting, supports the findings of benefits
by using dental professionals for cessation interventions
presented in the recent Cochrane-review [7]. The review
finds a significant effect of behavioral interventions versus
control for adult smokers in general dental practices with
6–12 months of follow-up (OR 2.38, 95% CI 1.70-3.35, no
evidence of heterogeneity [I2=3%]). Consequently, the
dental setting is a potential public health arena.
The majority of smokers quit and relapse a number of
times before they achieve sustained abstinence [5,6]. The
estimated annual incidence of relapse to smoking after
one year of abstinence is 2-15% in retrospective studies
(with recall problems) and about 10% in prospective
studies [19]. Zhu et al. show that multiple compared
with single counselling and, especially a self-help inter-
vention, significantly lower the relapse rate during the
first week, which in turn translates into a higher 12-
month abstinence rate [38]. This is in accordance with
our results that significantly more participants in HIT
than in LIT maintained sustained abstinence. We were
not able to comment on how the participants in the
present study possibly quit and relapsed, since we de-
cided not to use the quitting attempts information. The
reasons were the long follow-up period, adherent recall
bias problems [39], a considerable internal drop-outs on
the question of quitting attempts, and the study design
with no measurements between baseline, 12-month and
long-term follow-ups.
In the present study, abstinence at the 12-month follow-
up was a very strong predictor of abstinence at the long-
term follow-up, with ORs between 13.53 and 18.70 in the
multivariable logistic regression analyses. Program was
the only significant predictor of maintaining sustainedabstinence, with an OR of 2.67 for HIT vs. LIT. Among
common reported predictors for successful quitting
[6,16,17], only other support at the 12-month follow-up
was a significant predictor for point prevalence at the
long-term follow-up in the present study (Table 2).
Women had higher, however not statistically significant,
quitting rates than men in the present study. One explan-
ation can be that gender interacts with other support, as
women were significantly more likely than men to have
access to it. These gender differences in access to social
support correspond to population-based data from
Sweden assessing availability of emotional support [40].
We did not find any strong support for the positive
long-term effect of NRT use in the present study. No differ-
ence was detected in abstinence rates between those who
had used NRT ≥5 weeks and those who had not used NRT
at all, while those who had used NRT <5 weeks were
significantly less likely to be abstinent (Additional file 2:
Table S1, Additional file 3: Table S2). However, he study
was not designed to assess NRT use as such, so we are not
able to draw conclusions regarding the real-life effect of
NRT. Abstinence rates at 12 months are significantly im-
proved by NRT use in self-quitters without formal
behavioral support [15], as well as among those using NRT
≥5 weeks at the Swedish National Tobacco Quitline [14].
We did not detect such an effect at the 12-month follow-up
in our original study [28]. The contrasts concerning effect-
iveness of NRT in clinical trials [6,11,21] and population
studies [12,41] need further investigation not least in the
light of policy and economic coverage decisions.
The role of snus as a substitute for smoking was low
(≤8%) in the present study, and was not a significant
predictor for abstinence in the multivariable analyses.
Snus seems to play an insignificant role for cessation in
smokers with professional support [14,42], however, pre-
sumably plays a greater role in self-quitters [43].
The still smokers had reduced their number of smoked
cigarettes significantly, which can be seen as a step in the
process towards quitting [29,44]. And two-thirds of this
group intended to make a new quit attempt within the fol-
lowing six months. It is interesting what happened with
intention to quit from 12-month to long-term follow-up.
Among smokers at the 12-month follow-up who intended
to make a new quit attempt within the following six
months, 18% were smoke-free at the long-term follow-up.
However, among those who did not intend to quit at the
12-month follow-up, 36% were smoke-free at the long-
term follow-up (p=0.001).
The generalizability of a clinical trial is an important
issue. For the present study we approached adult daily
smokers fluent in the Swedish language and invited them
to participate. Those interested in smoking cessation were
then randomized [28]. This means that they were more
motivated to quit than smokers in the general population,
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quitline [14,45], and who have themselves taken contact
with a smoking cessation expert. Smoking ≤10 cigarettes/
day is a criterion reported to lead to exclusion for a large
percentage of individuals in clinical trials [46], but this was
not applied in the present study since it would have re-
duced the generalizability.
Strengths of the present study are: i) the randomized
controlled trial-design, ii) the long-term follow-up period,
and iii) the high response rate. Limitations are: i) the lack
of chemical validation of abstinence and ii) the risk of
memory bias. However, self-reports are considered accur-
ate in most smoking cessation studies [47] and as partici-
pants were free to use snus and NRT, it would be
problematic to distinguish low levels of smoking and use
of snus or NRT. Furthermore, we had no reason to as-
sume a different distribution of untruthful answers in the
two arms. The risk of memory bias increases with length
of follow-up and we noted discrepancies between baseline,
12-month, and long-term follow-up questionnaires re-
garding information of last date of smoking and number
of smoke-free days for 22 participants in HIT and 17 in
LIT (16% of all responders).
Conclusion
Abstinence at 12-month follow-up is a good predictor for
long-term abstinence. The difference in outcome between
HIT and LIT for smoking cessation, although non-
significant except for sustained abstinence, remained rela-
tively constant and in favour of HIT for at least 5–8 years
after the intervention.
Implications
A 12-month follow-up may be a sufficient end-point for
assessment of smoking cessation programs with fixed quit
dates. Also, which the present and the prior study suggests
[9,28], a relatively intensive program may be more effec-
tive and cost-effective than a less intensive program.Additional files
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